🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Call for ARSACS Research Proposals – Open to Researchers and Pharma. Funding up to $100,000 per project – Multiple projects may be funded! Apply now and share this opportunity. arsacs.com/research/

Scientists have created the first map of the crucial structures called mitochondria throughout the entire brain go.nature.com/4c2YMh0

🚀 Excited to share our latest article in #singlecell proteomics published in Cell! SC-pSILAC allows to simultaneously measure protein turnover and abundance in single cells, unlocking the first large-scale, 2D proteomic insights at single-cell resolution! cell.com/cell/fulltext/…

Tomorrow we host the Annual CRBS Bench-to-Bedside workshop titled "Cellular and Molecular Mechanisms of Aging", with Alanna Watt and Jeremy van Raamsdonk. Please register here: forms.gle/RKy5LxnrguYVUB…. There will be pizza!

Heterozygous RAB3A variants cause cerebellar ataxia by a partial loss-of-function mechanism academic.oup.com/brain/article-…

A pair of methods papers for studying synapses: DELTA: a method for brain-wide measurement of synaptic protein turnover reveals localized plasticity during learning Boaz Mohar (@[email protected]) karel svoboda @rhodamine110 Nelson Spruston Eugenio F. Fornasiero HHMI | Janelia Allen Institute nature.com/articles/s4159…

Trends in the drug target landscape for autoimmune diseases nature.com/articles/d4157… This new article analyses the evolving industry pipeline for autoimmune diseases, with a focus on emerging therapeutic targets

Do you do toxicology research? Come be my colleague (please!) apply to the Department of Pharmacology and Therapeutics McGill Medicine and Health Sciences Application is due in 9 days! mcgill.wd3.myworkdayjobs.com/en-US/McGill_C… Chemical Toxicology Chem. Res. Toxicol.

Proud of Cure Parkinson's for supporting this trial - immunosuppression in #Parkinsons with Azathioprine: cuh.nhs.uk/news/immunosup…

Save the date! Sir Venki Ramakrishnan (MRC-LMB, Cambridge, UK, Nobel Prize Chemistry 2009) will be speaking at the Research Institute of the MUHC (The Institute) on May 1st at 5pm. and the Montreal General Hospital on May 2nd at 11am. Full program and registration details to follow.

À ajouter à votre calendrier! Sir Venki Ramakrishnan (MRC-LMB, Cambridge, UK, prix Nobel de chimie 2009) prononcera une allocution au Research Institute of the MUHC (The Institute) le 1er mai à 17:00 et à l’Hôpital général de Montréal le 2 mai à 11:00. Le programme complet et les modalités d’inscription suivront.

What happens to all those alternative transcripts? 👉 Many are translated 👉 Proteolytic processing adds even more diversity Integrated mRNA & protein isoform landscape now out on bioRxiv! doi.org/10.1101/2025.0… #proteomics #transcriptomics #systemsbiology

Deep Learning-coupled Proximity Proteomics to Deconvolve Kinase Signaling In Vivo biorxiv.org/content/10.110…

cABL inhibition continues for #Parkinsons - Inhibikase Therapeutics licenses risvodetinib to ABLi Therapeutics which aims to continue developing it for PD fiercebiotech.com/biotech/former…

Large-scale plasma proteomic profiling unveils diagnostic biomarkers and pathways for Alzheimer’s disease nature.com/articles/s4358…

Excited to unveil Boltz-2, our new model capable not only of predicting structures but also binding affinities! Boltz-2 is the first AI model to approach the performance of FEP simulations while being more than 1000x faster! All open-sourced under MIT license! A thread… 🤗🚀

For readers interested in therapies for autoimmune diseases, this article in the June issue analyses trends in the drug target landscape nature.com/articles/d4157…

Please share: Seeking new Director of the historical Montreal Neurological Institute and Hospital (the Neuro)! Calling on neuroscience leaders across the globe - please consider applying to this important position. mcgill.wd3.myworkdayjobs.com/en-US/McGill_C…

For readers interested in GPCR drug discovery, here's a perspective on pharmacological characterization of GPCR modulators rdcu.be/esWfS and a review on functional dynamics studies revealing new approaches rdcu.be/esWgt

Results are in for the first trial of Ambroxol and Parkinson’s dementia. For years, the Parkinson’s community has waited for a trial to test whether ambroxol, a common cough medicine w/ brain penetrating effects could impact Parkinson’s disease dementia also called PDD. Just